137 completed. 137 Phase 2, 29 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 137 | Completed 137 |
| Phase 1 | 29 | Completed 29 |
| Phase 3 | 1 | Completed 1 |
Follow Neuroblastoma: new trials by email Literature Review of Neuroblastoma trials Research Report on Neuroblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). Bintrafusp alfa/M7824, Ibuprofen, PET scan - Olfactory Neuroblastoma, Esthesioneuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2022-06-21 | 2025-08-08 |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations ENV-101 (taladegib) - Solid Tumors With PTCH1 Loss-of-function Mutations | Phase 2 | Completed | Endeavor Biomedicines, Inc. | 20 | 2022-05-24 | 2026-03-05 |
| Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors Cryoablation Therapy, Nivolumab, Ipilimumab - Osteosarcoma, Ewing Sarcoma | Phase 2 | Completed | Children's National Research Institute | 5 | 2022-02-18 | 2025-01-01 |
| Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. Apatinib, Irinotecan, Temozolomide - Neuroblastoma | Phase 1 / Phase 2 | Completed | Sun Yat-sen University | 125 | 2021-08-26 | 2026-09-10 |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma Abemaciclib, Irinotecan, Temozolomide - Relapsed Solid Tumor, Refractory Solid Tumor | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 47 | 2020-11-09 | 2026-03-02 |
| A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma HITS, Naxitamab + GM-CSF cycles, NICE - Refractory Neuroblastoma, Soft Tissue Cancer | Phase 2 | Completed | Fundació Sant Joan de Déu | 47 | 2020-08-20 | 2024-08-29 |
| Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Palbociclib, Temozolomide, Irinotecan - Ewing Sarcoma, Solid Tumors | Phase 2 | Completed | Pfizer | 128 | 2019-05-24 | 2026-10-07 |
| Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin - Ganglioneuroblastoma, High Risk Neuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 42 | 2019-03-04 | 2026-06-02 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Oral Liquid 13-cis-retinoic Acid (13-CRA) Liquid 13-Cis Retinoic Acid, Extracted capsules 13-CRA - Neuroblastoma | Phase 1 / Phase 2 | Completed | Nova Laboratories Limited | 20 | 2018-04-17 | 2021-10-19 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Vemurafenib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2017-11-08 | 2025-01-27 |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2017-10-30 | 2025-02-05 |
| Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) 90Y-DOTA tyr3-Octreotide, 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan, Amino Acids - Neuroendocrine Tumors, Meningioma | Phase 2 | Completed | University of Iowa | 39 | 2017-09-29 | 2023-02-09 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages Cisplatin, Adjuvant Proton Radiotherapy, Endoscopic Resection - Paranasal Sinus Cancer, Nasal Cavity Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2017-09-01 | 2025-05-16 |
| A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma Hu3F8, GM-CSF, Isotretinoin - Neuroblastoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 59 | 2017-01-23 | 2025-10-07 |
| Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma metronomic therapy - Recurrent Neuroblastoma | Phase 2 | Completed | University of Cologne | 18 | 2016-12-22 | 2024-05-10 |
| Racotumomab in Patients With High-risk Neuroblastoma Racotumomab - Neuroblastoma | Phase 2 | Completed | Laboratorio Elea Phoenix S.A. | 39 | 2016-11-01 | 2023-09-11 |
Showing 20 of 137. Sign in to see all of them.
Sarcoma (31) · Medulloblastoma (24) · Osteosarcoma (24) · Wilms Tumor (24) · Rhabdomyosarcoma (22) · Central Nervous System Neoplasms (21) · Neuroectodermal Tumors, Primitive, Peripheral (20) · Lymphoma, Non-Hodgkin (19) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (18) · Burkitt Lymphoma (17) · Lymphoma (16) · Testicular Neoplasms (16) · Esthesioneuroblastoma, Olfactory (15) · Breast Neoplasms (14)
Neoplasms by Histologic Type (137) · Neoplasms, Glandular and Epithelial (137) · Neoplasms, Nerve Tissue (137) · Neoplasms, Germ Cell and Embryonal (136) · Neoplasms, Neuroepithelial (136) · Neuroectodermal Tumors (136) · Neuroectodermal Tumors, Primitive (135) · Neoplasms (127) · Neuroectodermal Tumors, Primitive, Peripheral (117) · Neoplasms by Site (69) · Neoplasms, Connective and Soft Tissue (46) · Nervous System Diseases (45) · Female Urogenital Diseases (37) · Female Urogenital Diseases and Pregnancy Complications (37) · Urogenital Diseases (37)
Cyclophosphamide (25) · Etoposide (21) · Filgrastim (19) · Carboplatin (18) · Doxorubicin (17) · Vincristine (15) · Cisplatin (14) · Isotretinoin (14) · Temozolomide (14) · Irinotecan (13) · Topotecan (13) · Peripheral Blood Stem Cell Transplantation (12) · Melphalan (11) · Radiotherapy (11) · sargramostim (11)
National Cancer Institute (NCI) (25) · Memorial Sloan Kettering Cancer Center (20) · Children's Oncology Group (13) · Fred Hutchinson Cancer Center (7) · Dana-Farber Cancer Institute (4) · European Infant Neuroblastoma Study Group - 1999 (4) · St. Jude Children's Research Hospital (4) · Duke University (3) · New Approaches to Neuroblastoma Therapy Consortium (3) · Sue O'Dorisio (3) · Baylor College of Medicine (2) · Eli Lilly and Company (2) · Fundació Sant Joan de Déu (2) · Giselle Sholler (2) · Gustave Roussy, Cancer Campus, Grand Paris (2)
United States (112) · Canada (23) · France (16) · United Kingdom (14) · Australia (12) · Italy (11) · Spain (11) · Switzerland (11) · Germany (10) · Puerto Rico (10) · Belgium (8) · Denmark (6) · Austria (5) · Netherlands (5) · Sweden (5)
Brian H. Kushner, MD (5) · Nai-Kong V. Cheung, MD, PhD (5) · Brian Kushner, MD (4) · Katherine K. Matthay, MD (3) · Frank Berthold, MD (2) · Gregory Yanik, MD (2) · Henry S. Friedman, MD (2) · Herve Rubie, MD (2) · John M. Maris, MD (2) · Mark W. Kieran, MD, PhD (2) · Rajen Mody (2) · Steven DuBois, MD (2) · Suzanne Shusterman, MD (2) · Tanya Trippett, MD (2)
PMID 31401903, PMID 23633099, PMID 11857322, PMID 11904735, PMID 14767498, PMID 16532433, PMID 16826357, PMID 17114659, PMID 17369569, PMID 17545536, PMID 17610262, PMID 19171715, PMID 19533657, PMID 19841031, PMID 20921469, PMID 20935224, PMID 20943374, PMID 21115869, PMID 21172879, PMID 21791630, PMID 22203761, PMID 22665539, PMID 23598171, PMID 24520094, PMID 25965900, PMID 26062933, PMID 26611425, PMID 27465021, PMID 28032129, PMID 28111925, PMID 28153957, PMID 28549783, PMID 29181270, PMID 30093449, PMID 30777875, PMID 30850872, PMID 31595663, PMID 32127657, PMID 32192573, PMID 32221013, PMID 32343642, PMID 32391579, PMID 32506485, PMID 32554315, PMID 33326254, PMID 33568345, PMID 33919763, PMID 34270348, PMID 34331515, PMID 34435684
U10CA098543 (11), U10CA180886 (9), P30CA006516 (3), UM1CA097452 (3), P30CA008748 (2), R01CA167632 (2), 2009 (1), 2019 (1), 2023 (1), N01CM62202 (1), P01CA081403 (1), P30CA006927 (1), P30CA016672 (1), P30CA043703 (1), P30CA054174 (1)